These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 26517178)

  • 1. Application of flow cytometry for myelodysplastic syndromes: Pitfalls and technical considerations.
    Alhan C; Westers TM; Cremers EM; Cali C; Ossenkoppele GJ; van de Loosdrecht AA
    Cytometry B Clin Cytom; 2016 Jul; 90(4):358-67. PubMed ID: 26517178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of flow cytometric immunophenotyping in myelodysplastic syndromes.
    Pagnucco G; Giambanco C; Gervasi F
    Ann N Y Acad Sci; 2006 Nov; 1089():383-94. PubMed ID: 17261782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia.
    Della Porta MG; Lanza F; Del Vecchio L;
    Cytometry B Clin Cytom; 2011; 80(4):201-11. PubMed ID: 21674774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood.
    Aalbers AM; van den Heuvel-Eibrink MM; Baumann I; Dworzak M; Hasle H; Locatelli F; De Moerloose B; Schmugge M; Mejstrikova E; Nováková M; Zecca M; Zwaan CM; Te Marvelde JG; Langerak AW; van Dongen JJ; Pieters R; Niemeyer CM; van der Velden VH
    Haematologica; 2015 Mar; 100(3):315-23. PubMed ID: 25425683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of bone marrow cells immunophenotypic study by flow cytometry in diagnosing myelodysplastic syndrome].
    Czyz A; Dworacki G; Komarnicki M
    Postepy Hig Med Dosw (Online); 2008 Jul; 62():354-63. PubMed ID: 18688206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias.
    Cremers EMP; Westers TM; Alhan C; Cali C; Wondergem MJ; Poddighe PJ; Ossenkoppele GJ; van de Loosdrecht AA
    Eur J Cancer; 2016 Feb; 54():49-56. PubMed ID: 26720403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multiparametric flow cytometry immunophenotypic scoring system for the diagnosis and prognosis of myelodysplastic syndromes.
    Huang J; Lai P; Zhou M; Weng J; Lu Z; Du X
    Clin Lab; 2012; 58(11-12):1241-51. PubMed ID: 23289195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of flow cytometric immunophenotyping in diagnosis of myelodysplastic syndromes--review].
    Zhang Y; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1477-81. PubMed ID: 19099668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
    Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
    Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling myelodysplastic syndromes by mass cytometry demonstrates abnormal progenitor cell phenotype and differentiation.
    Behbehani GK; Finck R; Samusik N; Sridhar K; Fantl WJ; Greenberg PL; Nolan GP
    Cytometry B Clin Cytom; 2020 Mar; 98(2):131-145. PubMed ID: 31917512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening bone marrow samples for abnormal lymphoid populations and myelodysplasia-related features with one 10-color 14-antibody screening tube.
    Rajab A; Porwit A
    Cytometry B Clin Cytom; 2015; 88(4):253-60. PubMed ID: 25664445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A series of case studies illustrating the role of flow cytometry in the diagnostic work-up of myelodysplastic syndromes.
    Westers TM; Saft L; van der Velden VHJ; Te Marvelde JG; Dunlop A; Ireland R; Valent P; Porwit A; Béné MC; van de Loosdrecht AA
    Cytometry B Clin Cytom; 2023 Jan; 104(1):87-97. PubMed ID: 35179296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single-centre real-life experience.
    Majcherek M; Kiernicka-Parulska J; Mierzwa A; Barańska M; Matuszak M; Lewandowski K; Komarnicki M; Czyż A
    Scand J Immunol; 2021 Aug; 94(2):e13028. PubMed ID: 33577137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group.
    Westers TM; Ireland R; Kern W; Alhan C; Balleisen JS; Bettelheim P; Burbury K; Cullen M; Cutler JA; Della Porta MG; Dräger AM; Feuillard J; Font P; Germing U; Haase D; Johansson U; Kordasti S; Loken MR; Malcovati L; te Marvelde JG; Matarraz S; Milne T; Moshaver B; Mufti GJ; Ogata K; Orfao A; Porwit A; Psarra K; Richards SJ; Subirá D; Tindell V; Vallespi T; Valent P; van der Velden VH; de Witte TM; Wells DA; Zettl F; Béné MC; van de Loosdrecht AA
    Leukemia; 2012 Jul; 26(7):1730-41. PubMed ID: 22307178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system.
    Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
    Leukemia; 2016 Mar; 30(3):658-65. PubMed ID: 26503643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter comparison of CD34+ myeloid cell count by flow cytometry in low-risk myelodysplastic syndrome. Is it feasible?
    Font P; Subirá D; Matarraz S; Benavente C; Cedena MT; Morado M; Pérez Corral A; Bellón JM; Díez-Martín JL
    Cytometry B Clin Cytom; 2018 May; 94(3):527-535. PubMed ID: 28618451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of flow cytometry in diagnostics of myelodysplastic syndromes--beyond the WHO 2008 classification.
    Porwit A
    Semin Diagn Pathol; 2011 Nov; 28(4):273-82. PubMed ID: 22195405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a Bone Marrow Dysmyelopoiesis Immunophenotypic Index for the Diagnosis and Prognosis of Myelodysplastic Syndromes.
    Verigou E; Lampropoulou P; Smyrni N; Kolliopoulou G; Sakellaropoulos G; Starakis I; Zikos P; Solomou E; Symeonidis A; Karakantza M
    Cardiovasc Hematol Disord Drug Targets; 2015; 15(2):148-61. PubMed ID: 26126819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Application of flow cytometry in detecting dysplasia of myelodysplastic syndromes].
    Li J; He GS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):1069-72. PubMed ID: 23998614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells.
    Ogata K; Sei K; Saft L; Kawahara N; Porta MGD; Chapuis N; Yamamoto Y
    Leuk Res; 2018 Aug; 71():75-81. PubMed ID: 30025279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.